Gene by Gene, which develops consumer DNA testing products for ancestry and genealogy applications, has acquired Arpeggi, a developer of solutions for genome sequencing, data management and computational analysis.

The combined company will enable the acceleration of a suite of affordable genetics testing and diagnostics services available to consumers, researchers and healthcare providers. 

Arpeggi develops solutions for genome sequencing, data management and computational analysis. In April, the company released GCAT ­ Genome Comparison and Analytic Testing, a free community-driven platform for evaluating the performance of next­-generation sequencing (NGS) data analysis methods. Arpeggi has developed proprietary sequencing tools, designed for scale, that enable accurate, fast and cost-­effective analysis of genomes. This year, Arpeggi was selected as one of 14 startups, out of 400 applicants, to join the StartUp Health and GE Entrepreneurship Program to help grow, commercialize and scale new innovative healthcare technologies.

"The deluge of data generated from genomic testing and the ability to store, analyze and interpret it efficiently has been a bottleneck for organizations focused on large scale sequencing,” said Rafael Torres, senior managing director, GE Ventures Healthcare. “Arpeggi's solution provides an infrastructure that helps human genomic and bioinformatics companies get the most out of their data.”

Arpeggi will be incorporated into Gene by Gene. Additionally, Arpeggi's founders will join Gene by Gene's management team, effective immediately. Arpeggi's Nir Leibovich was named chief business officer, Jason Wang was named chief technology officer and David Mittelman, Ph.D., was named chief scientific officer. Gene by Gene's Doron Behar, M.D., Ph.D., was named chief medical officer.